- Viracta Therapeutics Inc To Host R&D Day TranscriptOct 04, 2023
- Viracta Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call TranscriptApr 27, 2022
- Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call TranscriptNov 30, 2020
- Q3 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 16, 2020Earnings
- Q2 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2020Earnings
- Q1 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020Earnings
- Q4 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2020Earnings
- Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale TranscriptNov 13, 2019
- Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 12, 2019Earnings
- Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019Earnings
- Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019Earnings
- Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019Earnings
Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
© -
Good afternoon, everyone. My name is Vik Chopra at -- with Crédit Suisse. Very happy to have Mr. Willie Quinn, the CFO of Sunesis Pharmaceuticals. Thanks for being with us.
Good afternoon. Happy to be here and give you a quick update on Sunesis Pharmaceuticals. Before I begin, I want to remind everyone that I will be making forward-looking statements, and you should review our filings with the SEC for more details, our most recent 10-Q was filed for the quarter ended September 30, 2019.
Sunesis is an oncology development company focused on kinase inhibitors. We have an exciting noncovalent BTK inhibitor in development, and I'll spend most of my time talking about that. We also have a PDK1 inhibitor. I'll tell you a little bit about that. And then we have a pan-Raf inhibitor, which is currently in the hands of Takeda, and they are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)